頭頸部扁平上皮がんにおける細胞治療 - パイプライン分析：2024年

養子細胞療法（ACT）は、様々ながんの初期段階の試験で有望な結果を示しています。しかし、頭頸部扁平上皮がん（HNSCC）の治療で成功したアプローチは、固形がんに共通する特有の課題に直面しています。これらの課題には、T細胞が腫瘍を効果的に標的とするための適切なホーミング機構を確立する必要性、強固な免疫応答のための腫瘍内への十分なT細胞浸潤の確保、腫瘍外への影響を引き起こさない抗原の同定などが含まれます。HNSCCに対するACTアプローチはまだ初期段階にあるが、近い将来、治療において重要な役割を果たすようになるという楽観的な見方もあります。これは、化学療法不応の患者に対するチェックポイント阻害剤との併用や、再発転移の一次治療における可能性があります。

分析によると、開発パイプラインには、TCR T細胞療法、腫瘍浸潤リンパ球（TILs）、免疫チェックポイント阻害剤（ICI）との併用アプローチなど、HNSCCの治療に役立つさまざまな細胞療法があります。

当レポートでは、頭頸部扁平上皮がんにおける細胞治療について調査し、市場機会、主要競合分析、企業のパイプライン医薬品プロファイル、臨床試験、その他の発展動向などをまとめています。

目次

第1章 レポートの概要

第2章 頭頸部扁平上皮がん（HNSCC）における細胞治療標的の背景

• 頭頸部扁平上皮がん（HNSCC）における養子細胞療法
• 養子細胞療法の種類
• 頭頸部扁平上皮がんにおけるCAR-T療法
• 頭頸部扁平上皮がんにおけるCAR-NK細胞療法
• 頭頸部扁平上皮がんにおけるTCR T細胞療法
• 頭頸部扁平上皮がんにおけるTIL療法

第3章 頭頸部扁平上皮がん（HNSCC）における細胞治療のパイプライン分析

第4章 臨床試験と研究

• 頭頸部扁平上皮がんにおける細胞治療臨床試験、地域別
• HNSCC細胞療法単独療法と併用療法臨床試験
• 臨床および規制のタイムライン
• 後期段階のプロファイル比較の概要

第5章 ライセンシング、取得、コラボレーション

第6章 パイプラインの情勢

• HNSCCパイプラインにおける細胞療法の薬剤プロファイル- 概要
• 第II相
• 第I/II相
• 第I相
• 前臨床
• 創薬

第7章 HNSCCにおける細胞療法のSWOT分析

第8章 付録

The Cell Therapies in Head and Neck Squamous Cell Carcinoma - Pipeline Analytics -2024 report published by Mellalta Meets covers the Cell Therapies market opportunity providing Key Competitive Analysis, 17+ Companies with Pipeline Drug Profiles, Clinical Trials, Other Developments (Collaboration Details, Funding, etc.), Licensing and Agreements, Business Agreement, Business Partner as well as Clinical Partner. Reports cover pipeline product analysis by stage of development, competitive landscape by phases, companies, clinical trials by regions, cell therapy modalities, and intervention type. Cell Therapies in Head and Neck Squamous Cell Carcinoma-Pipeline Analytics report adds value in terms of describing clinical-stage products for their clinical & regulatory timelines as well as in terms of providing the current market opportunity, drivers, and challenges.

Adoptive cell therapies (ACT) have demonstrated promising outcomes in early-stage trials across various cancers. However, successful approaches in treating HNSCC face specific challenges commonly found in solid tumors. These challenges include the necessity to establish appropriate homing mechanisms for T cells to effectively target the tumor, ensuring adequate T-cell infiltration into the tumor for a robust immune response, and identifying antigens that will not lead to off-tumor effects. While ACT approaches are still in their early stages for HNSCC, there is optimism that they will soon play a significant role in treatment. This may involve potential combinations with checkpoint inhibitors for patients with chemotherapy-refractory disease and potentially in the first-line recurrent metastatic setting.

In this report, Mellalta Meets provides an in-depth analysis of the Cell Therapies in the HNSCC Pipeline covering preclinical and clinical studies, details of partnerships and business deal values, targeted technologies and therapy areas, investments, and acquisition trends. Currently, there are more than 17 candidates in the Cell Therapies in the HNSCC Pipeline under evaluation in clinical and preclinical studies. The major key players operating in the market are Iovance Biotherapeutics, ImmunityBio, Rapa Therapeutics, TCRCure Biopharma, Immatics, and many more which have a robust clinical pipeline of cell therapy candidates for HNSCC.

As per analysis, the development pipeline is full of different cell therapy modalities like TCR T-cell therapies, tumor-infiltrating lymphocytes (TILs), and combination approaches with immune checkpoint inhibitors (ICI) which can help in addressing HNSCC.

Mellalta's HER2-Low Breast Cancer Pipeline Report - Key Highlights

There are 5 products in the Phase 2 and Phase 1/2 stage of development, representing 15% of the total share of the developing Cell Therapies in HNSCC.

The HNSCC cell therapies landscape is dominated by Phase 1 stage assets accounting for 54.55% followed by Discovery stage products which account for 24.24%.

To be continued...

Report Coverage:

Indication Prioritization: HNSCC market potential

Business Transactions & Strategies: Key collaborations and deal values

HNSCC Cell Therapies Pipeline Development: Product Profiles, Clinical Trials & Results

HNSCC Cell Therapies Acquisition Targets

HNSCC Cell Therapies Competitive Intelligence

Recent and upcoming events

Table of Content

1.Report Overview

2.The Cell Therapies in HNSCC Target Background

• 2.1.Adoptive Cell Therapies in HNSCC
• 2.2.Types of Adoptive Cell Therapies
• 2.3.CAR-T Therapy in HNSCC
• 2.4.CAR-NK cell therapy in HNSCC
• 2.5.TCR T-cell therapy in HNSCC
• 2.6.TIL Therapy in HNSCC

3.Cell Therapies in HNSCC Pipeline Analysis

• 3.1.Development Overview
• 3.2.Pipeline Products by Stage of Development
• 3.3.Cell Therapies in HNSCC Competitive Landscape
• 3.4.Pipeline Products by Company and Region
• 3.5.Type of Cell Therapies in HNSCC Pipeline Landscape

4.Clinical Trials and Research

• 4.1.Cell Therapies Clinical Trials in HNSCC by Region
• 4.2.HNSCC Cell therapies Monotherapy & Combinations Clinical Trials
• 4.3.Clinical & Regulatory Timelines
• 4.4.Late-Stage Profiles Comparisons At-a-glance

5.Licensing, Acquisition, and Collaboration

• 5.1.Cell Therapies in HNSCC Licensing, Acquisition, and Deal Values
• 5.2.Licensing by Transaction Type and Total Amount Size by Phases

6.Pipeline Landscape

• 6.1.Cell Therapies in HNSCC Pipeline Drug Profiles- at a glance
• 6.2.Phase II
  • 6.2.1.LN-145
    • 6.2.1.1.Product Profile
    • 6.2.1.2.Clinical Trial Details
  • 6.2.2.PD-L1 T-haNK
    • 6.2.2.1.Product Profile
    • 6.2.2.2.Clinical Trial Details
• 6.3.Phase I/II
  • 6.3.1.RAPA-201
    • 6.3.1.1.Product Profile
    • 6.3.1.2.Clinical Trial Details
  • 6.3.2.EBV TCR-T
    • 6.3.2.1.Product Profile
    • 6.3.2.2.Clinical Trial Details
  • 6.3.3.IMA402
    • 6.3.3.1.Product Profile
    • 6.3.3.2.Clinical Trial Details
• 6.4.Phase I
  • 6.4.1.HRYZ-T101
    • 6.4.1.1.Product Profile
    • 6.4.1.2.Clinical Trial Details
  • 6.4.2.TSC-200-A0201
    • 6.4.2.1.Product Profile
    • 6.4.2.2.Clinical Trial Details
  • 6.4.3.P-MUC1C-ALLO1
    • 6.4.3.1.Product Profile
    • 6.4.3.2.Clinical Trial Details
  • 6.4.4.NT-175
    • 6.4.4.1.Product Profile
    • 6.4.4.2.Clinical Trial Details
  • 6.4.5.TSC-201-B0702
    • 6.4.5.1.Product Profile
    • 6.4.5.2.Clinical Trial Details
  • 6.4.6.Uzatresgene autoleucel
    • 6.4.6.1.Product Profile
    • 6.4.6.2.Clinical Trial Details
  • 6.4.7.TSC-203-A0201
    • 6.4.7.1.Product Profile
    • 6.4.7.2.Clinical Trial Details
  • 6.4.8.TSC-204-A0201
    • 6.4.8.1.Product Profile
    • 6.4.8.2.Clinical Trial Details
  • 6.4.9.TSC-204-C0702
    • 6.4.9.1.Product Profile
    • 6.4.9.2.Clinical Trial Details
  • 6.4.10.TSC-204-A0101
    • 6.4.10.1.Product Profile
    • 6.4.10.2.Clinical Trial Details
  • 6.4.11.TBio-4101
    • 6.4.11.1.Product Profile
    • 6.4.11.2.Clinical Trial Details
  • 6.4.12.CRTE7A2
    • 6.4.12.1.Product Profile
    • 6.4.12.2.Clinical Trial Details
  • 6.4.13.AGX-148
    • 6.4.13.1.Product Profile
    • 6.4.13.2.Clinical Trial Details
  • 6.4.14.NEXI-003
    • 6.4.14.1.Product Profile
    • 6.4.14.2.Clinical Trial Details
  • 6.4.15.IMA401
    • 6.4.15.1.Product Profile
    • 6.4.15.2.Clinical Trial Details
  • 6.4.16.WU-NK-101
    • 6.4.16.1.Product Profile
    • 6.4.16.2.Clinical Trial Details
  • 6.4.17.IMA203
    • 6.4.17.1.Product Profile
    • 6.4.17.2.Clinical Trial Details
  • 6.4.18.IMA-203CD8
    • 6.4.18.1.Product Profile
    • 6.4.18.2.Clinical Trial Details
• 6.5.Preclinical
  • 6.5.1.ADP-600
  • 6.5.2.IMA204
• 6.6.Discovery
  • 6.6.1.TSC-200-C0702
  • 6.6.2.TSC-201-A0201
  • 6.6.3.TSC-201-A2402
  • 6.6.4.TSC-202-A0201
  • 6.6.5.TSC-203-B0702
  • 6.6.6.TSC-204-A0301
  • 6.6.7.TSC-204-B0702
  • 6.6.8.TSC-203-A2402

7.Cell Therapies in HNSCC SWOT Analysis

8.Appendix

• 8.1.About us